A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

This study has been withdrawn prior to enrollment.

(Due to company decision to focus resources on a larger, controlled study in this patient population.)

Sponsor:

Collaborator:

Ortho Biotech Clinical Affairs, L.L.C.

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT00446602

First received: March 12, 2007

Last updated: June 9, 2011

Last verified: June 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	August 2009
Estimated Primary Completion Date:	No date given